BCM-95® CG Bioavailability

ALWAYE, India—A clinical study published in the Indian Journal of Pharmaceutical Science assessed the bioavailability of curcuminoids and tested a patented formulation, BCM-95® CG from Dolcas-Biotech Inc., on a human volunteer group. Normal curcumin was used in the control group. After a washout period of two weeks the control group and drug group were crossed over BCM-95 CG and curcumin, respectively. Researchers also compared a combination of curcumin-lecithin-piperine, which was earlier shown to provide enhanced bioavailability. The relative bioavailability of BCM-95 CG (Biocurcumax™) was about 6.93-fold compared to normal curcumin and about 6.3-fold compared to curcumin-lecithin-piperine formula. It was concluded that BCM-95 CG has potential for widespread application for various chronic diseases.